Takeya Adachi received an M.D. from Keio University School of Medicine, Tokyo, Japan, and majored in medicine to shed light on novel immunological insights in the context of skin T cell homeostasis and lymphoma (Nat. Med. 2015) and received a Ph.D. in Keio University Graduate School of Medicine in 2016. His research interests include dermatology, immunology, allergy as well as rare and intractable drug hypersensitivities, and since 2020, he has promoted international collaborative research with the Immunologie, Immunopathologie et Chimie Thérapeutique, CNRS UPR3572, Institut de Biologie Moléculaire et Cellulaire (IBMC), Université de Strasbourg, France, as its former Professeur invité.

Upon his experience as a scientific officer at the secretariat of the Human Frontier Science Program (HFSP), a program officer in the Japanese governmental R&D funding agency, AMED (EJHG 2017, OJRD 2018, Springer-Nature White Paper 2019), and an Interdisciplinary Scientific Committee member of the International Rare Diseases Research Consortium (IRDiRC), he is in charge of the ENGAGE Task Force supported by the Ministry of Health, Labour and Welfare of Japan to implement a national research strategy toward 2030 for allergy/immunology (Allergol Int 2020).

Currently, he is taking the lead role in developing the Cross-Reality (XR) platform and novel impact analysis (Allergy 2022), promoting science without borders to form a society in which people live long, healthy lives, that is.